R. Whitham

A. Montanaro, R. Whitham, W. Johnston, 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Episodic changes in T‐cell frequencies to myelin basic protein in patients with multiple sclerosis

D. Bourdette, A. Vandenbark, H. Offner, 1993, Neurology.

Epitope specificity and V gene expression of cerebrospinal fluid T cells specific for intact versus cryptic epitopes of myelin basic protein

D. Bourdette, A. Vandenbark, H. Offner, 1993, Journal of Neuroimmunology.

Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis

D. Bourdette, A. Vandenbark, H. Offner, 1992, Journal of Neuroimmunology.

Transforming growth factor-beta enhances the in vivo effector function and memory phenotype of antigen-specific T helper cells in experimental autoimmune encephalomyelitis.

A. Weinberg, S. Swain, H. Offner, 1992, Journal of immunology.

Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity-determining region 2 peptides from disease-associated T cell receptor BV genes.

D. Bourdette, G. Nepom, A. Vandenbark, 1998, Journal of immunology.

Genes * from Disease-Associated T Cell Receptor BV Complementarity-Determining Region 2 Peptides Sclerosis . III . Preferential Immunogenicity of Immunity to T Cell Receptor Peptides in Multiple

D. Bourdette, G. Nepom, A. Vandenbark, 1998 .

Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis.

T. Vollmer, G. Francis, W. Sheremata, 1997, Archives of neurology.

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry

Daniel M. Hartung, Dennis N. Bourdette, D. Bourdette, 2015, Neurology.

Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study

C. Murchison, R. Whitham, M. Cameron, 2014, Multiple sclerosis.

The Multiple Sclerosis Surveillance Registry: A Novel Interactive Database Within the Veterans Health Administration.

J. Haselkorn, M. Wallin, R. Whitham, 2020, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

Therapeutic vaccination with a trivalent T‐cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis

D. Bourdette, A. Vandenbark, H. Offner, 2008, Immunology.

The contemporary spectrum of multiple sclerosis misdiagnosis

Gregory F. Wu, B. Weinshenker, A. Cross, 2016, Neurology.

Contemporary Issues

Daniel M. Hartung, Dennis N Bourdette, D. Bourdette, 2002 .

American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study

D. Bourdette, J. Lovera, L. Schaben, 2011, Multiple sclerosis.

Treatment of multiple sclerosis with T–cell receptor peptides: Results of a double–blind pilot trial

D. Bourdette, A. Vandenbark, H. Offner, 1996, Nature Medicine.

Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials

J. Simon, R. Priore, L. Jacobs, 1998, Multiple sclerosis.

Author response.

Daniel M. Hartung, D. Bourdette, R. Whitham, 2015, Neurology.

Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial

K. Wild, D. Bourdette, O. Stuve, 2010, Multiple Sclerosis.

Correlations of Perceived Deficits Questionnaire of Multiple Sclerosis Quality of Life Inventory with Beck Depression Inventory and neuropsychological tests.

B. Oken, K. Wild, D. Bourdette, 2006, Journal of rehabilitation research and development.

Reducing survey burden: feasibility and validity of PROMIS measures in multiple sclerosis

D. Bourdette, D. Hanes, R. Whitham, 2014, Multiple sclerosis.

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis

R. P. Kinkel, D. L. Cookfair, R. Herndon, 1997, Neurology.

Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis 1 Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc. 1

C. Granger, R. Herndon, R. Kinkel, 1999, Journal of Neuroimmunology.

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

J H Simon, A L Scherzinger, C. Granger, 1998, Annals of neurology.

Premature osteoporosis in multiple sclerosis implications for corticosteroid therapy

D. Bourdette, M. McClung, R. Whitham, 1990 .

Access to Multiple Sclerosis Specialty Care

J. Haselkorn, A. Turner, R. Whitham, 2013, PM & R : the journal of injury, function, and rehabilitation.

Exploring educational needs of multiple sclerosis care providers: Results of a care-provider survey.

J. Haselkorn, M. Hatzakis, D. Bourdette, 2006, Journal of rehabilitation research and development.

TCR peptide therapy regulates basic protein specific T cell frequency in patients with multiple sclerosis

D. Bourdette, A. Vandenbark, H. Offner, 1991, Journal of Neuroimmunology.

Author response.

Daniel M. Hartung, D. Bourdette, R. Whitham, 2015, Neurology.

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry

Daniel M. Hartung, Lippincott Williams Wilkins, L. Wilkins, 2015, Neurology.

Immunity to TCR peptides in multiple sclerosis: II. T cell recognition of Vb5.2 and Vb6.1 CDR2 peptides

R. Whitham, Y. Chou, G. Hashim, 1994, Journal of Immunology.

Multiple Sclerosis and Vitamin D: A Review and Recommendations

R. Whitham, A. Solomon, 2010, Current neurology and neuroscience reports.